The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

A simple, sensitive and reproducible spectrophotometric method was developed for the determination of sitagliptin phosphate in bulk and in pharmaceutical formulations. The proposed method is based on ...

These four tutorials will completely change how you draw eyes. Learn essential techniques for structure, proportions, shading, and expression that help bring eyes to life and make your drawings more ...

For people with chronic kidney disease (CKD) (long-term damage to the kidneys that reduces their ability to filter blood), also having diabetes (a lifelong condition that causes a person's blood sugar ...

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

5 Catholic Kwandong University College of Medicine Department of Medical Science, Gangneung-si, The Republic of Korea Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) have been reported to ...

CLINICAL QUESTION: Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as add-on therapy for diabetes, increase the risk of amputations, stent placement, or revascularization surgeries compared ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Abstract: Dipeptidyl peptidase 4 (DPP-4) are drug targets for type-2 diabetes mellitus (T2DM). The enzyme dipeptidyl peptidase 4 (DPP-4) can catalyze the decrease in the hormone incretin peptide, ...